Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11160283 | 0.79 | NR3C1 (0.43) | NR3C1TSHRCYP2C19KMT2AMEN1 | |
| SCHEMBL11041424 | 0.78 | HSP90AA1 (0.40) | NR3C1TSHRTRPA1CYP2C19KMT2A | |
| SCHEMBL1533790 | 0.77 | TSHR (0.48) | NR3C1TSHRCYP2C19ADRA2BADRA2C | |
| SCHEMBL9749583 | 0.75 | TSHR (0.50) | NR3C1TSHRCYP2C19KMT2APGR | |
| SCHEMBL7148219 | 0.73 | TSHR (0.54) | NR3C1TSHRCYP2C19PGRNR3C2 | |
| SCHEMBL3043989 | 0.73 | TSHR (0.50) | TSHRTRPA1SLC6A2ALDH1A1HPGD | |
| SCHEMBL11872119 | 0.71 | TRPA1 (0.46) | NR3C1TSHRTRPA1CYP2C19KMT2A | |
| SCHEMBL4971557 | 0.70 | TSHR (0.42) | NR3C1TSHRTRPA1CYP2C19KMT2A | |
| SCHEMBL7405137 | 0.70 | NR3C1 (0.39) | NR3C1KMT2AMEN1PGRNR3C2 | |
| SCHEMBL11348653 | 0.70 | TSHR (0.41) | NR3C1TSHRCYP2C19ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226932-B2 | Self-emulsifying drug delivery system | G.D. SEARLE LLC (US) | 2007-06-05 | — | — | US | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-6974876-B2 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040048934-A1 | Self-emulsifying drug delivery system | G.D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-12-04 | — | — | US | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0769936-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEM | G.D. SEARLE & CO. (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0641333-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996003113-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEM | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0641333-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023388-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | NR3C1 4064/4885TSHR 4812/4885TRPA1 4868/4885 |
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | NR3C1 3762/4885TSHR 4576/4885TRPA1 4755/4885 |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | NR3C1 4067/4885TSHR 4807/4885TRPA1 4863/4885 |
| US-20040048934-A1 | Self-emulsifying drug delivery system | LIPA, CEL, LSS | NR3C1 3928/4885TSHR 4205/4885TRPA1 4697/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | NR3C1 3895/4885TSHR 4635/4885TRPA1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.